Eli Lilly and Company $LLY Shares Sold by Hardman Johnston Global Advisors LLC

Hardman Johnston Global Advisors LLC cut its holdings in Eli Lilly and Company (NYSE:LLY) by 35.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,447 shares of the company’s stock after selling 6,302 shares during the quarter. Hardman Johnston Global Advisors LLC’s holdings in Eli Lilly and Company were worth $8,734,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Sumitomo Mitsui Financial Group Inc. purchased a new stake in shares of Eli Lilly and Company during the second quarter worth about $27,000. Evolution Wealth Management Inc. acquired a new stake in Eli Lilly and Company during the second quarter worth approximately $29,000. Steph & Co. grew its stake in Eli Lilly and Company by 290.0% in the 3rd quarter. Steph & Co. now owns 39 shares of the company’s stock worth $30,000 after acquiring an additional 29 shares during the period. Financial Gravity Companies Inc. purchased a new stake in Eli Lilly and Company in the 2nd quarter worth approximately $31,000. Finally, Bare Financial Services Inc raised its holdings in Eli Lilly and Company by 263.6% in the 2nd quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock valued at $31,000 after acquiring an additional 29 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly’s announced acquisition of Ventyx Biosciences offered a strategic complement to its weight‑loss franchise by targeting inflammation (data showed benefit when combined with GLP‑1 therapy); the deal helped calm investor concern after the Novo news and supported a rally. Eli Lilly Stock Rallies as Ventyx Deal Calms Wegovy Concerns
• Positive Sentiment: Lilly and NVIDIA will fund a $1B AI co‑innovation lab over five years to speed drug discovery and manufacturing—this could lower R&D costs and shorten time‑to‑market for new drugs, a multi‑year positive for pipeline value. Nvidia, Eli Lilly to spend $1 billion over five years on joint research lab
• Positive Sentiment: Commercial demand traction: Humana’s CenterWell Pharmacy launching an employer program that uses Lilly’s GLP‑1 drugs underscores ongoing demand and distribution pathways for Lilly’s marketed products. Humana’s CenterWell Pharmacy Launches Employer Venture Using Lilly’s GLP-1 Drugs
• Neutral Sentiment: Company guidance and seasonality: Analysts expect double‑digit Q4 growth and Lilly has strong FY 2025/26 earnings expectations—these set a positive baseline but already appear priced into the stock. What to Expect From Eli Lilly’s Q4 2025 Earnings Report
• Neutral Sentiment: Lilly says it is confident about supply readiness for its oral weight‑loss candidate ahead of an anticipated U.S. approval—reduces one operational risk but doesn’t remove competitive or regulatory uncertainty. Lilly says it’s confident in weight-loss pill supply ahead of U.S. approval
• Negative Sentiment: Competitive pressure: Novo Nordisk’s immediate nationwide rollout of the Wegovy oral pill surprised some investors and triggered a pullback in LLY shares as markets priced higher competition in the oral GLP‑1 market. Eli Lilly Stock Rallies as Ventyx Deal Calms Wegovy Concerns

Analyst Ratings Changes

Several equities analysts recently weighed in on the company. Scotiabank started coverage on Eli Lilly and Company in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $1,165.00 target price on the stock. Leerink Partners set a $1,234.00 price objective on shares of Eli Lilly and Company in a research note on Monday, January 5th. CICC Research increased their target price on Eli Lilly and Company from $801.00 to $1,060.00 and gave the stock a “neutral” rating in a research report on Thursday, November 13th. Deutsche Bank Aktiengesellschaft lifted their target price on Eli Lilly and Company from $1,000.00 to $1,200.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. Finally, Berenberg Bank upped their price target on Eli Lilly and Company from $830.00 to $950.00 and gave the stock a “hold” rating in a research note on Tuesday, December 2nd. Five investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, Eli Lilly and Company presently has a consensus rating of “Buy” and an average target price of $1,169.00.

Eli Lilly and Company Stock Down 0.5%

Shares of Eli Lilly and Company stock opened at $1,075.90 on Wednesday. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,133.95. The stock has a market cap of $1.02 trillion, a price-to-earnings ratio of 52.64, a price-to-earnings-growth ratio of 0.78 and a beta of 0.35. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71. The company has a fifty day moving average price of $1,044.24 and a 200 day moving average price of $865.79.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The company had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. During the same period last year, the company posted $1.18 earnings per share. The firm’s revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Equities research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be issued a $1.73 dividend. The ex-dividend date is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 33.86%.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.